CPDD President’s Column

FRANK J. VOCCI, PH.D.
PRESIDENT

I began my term as CPDD President at the end of the 2013 scientific meeting after being the President-Elect for a year and a half. During my time as President-Elect I received counsel and on-the-job training from Scott Lukas, Rich De la Garza, Ted Cicero, Marty Adler, and Ellen Geller. Thanks to them I feel like I’ve received a course in the inner workings of the College. I had the good fortune of watching Scott Lukas and Rick de la Garza presiding over their terms as President. I am grateful for their mentorship and feel comfortable beginning my one-year tenure.

A point that can’t be overstressed is that the College is in good financial shape and runs extremely well. This is due to the hard work and stewardship of Marty Adler and Ellen Geller and their staff in the CPDD Executive Office. Running an office effectively and efficiently is like putting on a stage production. The better it works the less people are aware of what’s going on behind the scenes.

One of my main responsibilities as President-Elect was to solicit volunteers for the various committees and to replace the outgoing chairs of certain committees. I would like to thank the following individuals who chaired committees and have now rotated off these committees: Toby Eisenstein (Animals in Research), Suzette Evans (Awards), Ron Cowan (Credentials), Kathleen Brady (Education, Outreach, and Public Policy), Anne Andorn (Industry, Academia, and Government Relations), Mark Kauffman (Media Relations), Van King (Membership), Sandy Comer (Program), and Stephanie Collins-Reed (Travel Awards). I would also like to thank the following individuals for assuming the chair of the following committees: Marilyn Carroll (Animals in Research), Mark Smith (Awards), Dave Penetar (Credentials), Dennis McCarty (Education, Outreach, and Public Policy), Beatriz Rocha (Industry, Academia, and Government Relations), Bertha Madras (Media Relations), Teresa Franklin (Membership), Elise Weerts (Program), and Jennifer Havens (Travel Awards). Also thanks to the members who volunteered for and are now new committee members.

The 2014 meeting

We will be returning to the Caribe Hilton in San Juan, Puerto Rico next
President’s Column continued from page 1

June for the 76th meeting of the College. I have been to several CPDD meetings held at the Caribe Hilton and have always enjoyed this venue. The meeting facilities at this hotel are excellent and the hotel has many amenities on its grounds. Proposals for symposia, mini-symposia and workshops are due by October 15. Since many proposals are submitted, the Program Committee always has a difficult job of selecting the most interesting topics for the symposia and workshops. I expect that the scientific program will be outstanding.

Challenges for the next year and beyond

As we are all aware, the creation of the NIH institute on addictions was changed to a functional integration of research across several institutes. In these financially uncertain times this is probably the best outcome as there were concerns that a merger would result in the loss of funding to the new institute or various NIDA and NIAAA research programs would be sent to new institutes that had different priorities.

The biggest challenge we face as a field is restricted Federal funding for substance abuse research. With the sequestration of this year’s Federal budget, NIDA lost $ 60 million dollars. President Obama’s budget for FY 2014 is requesting a 1.5 % increase over the FY 2012 level. This would be an increase of $ 78 million over the FY 2013 budget. CPDD works with the Friends of NIDA and Van Scyoc and Associates to develop strategies to lobby Congress for research funds in general and for NIDA and NIH in particular. We, as an organization, will be lobbying for restoration and increases for the research budget. As constituents, you can also lobby your congressman and senators. You have the right to make appointments and discuss the importance of drug abuse research, which is essentially a publicly funded enterprise.

As mentioned previously, the College is in excellent financial shape. The operating budget of the College usually covers the yearly expenses. Moreover, the College has a large fund balance. One new element added to the financial stewardship of the College is the creation of the Finance Committee that is chaired by Ted Cicero, the CPDD Treasurer. This committee was created to maintain the excellent financial position of the College and to help in managing the financial aspects of the transition that will occur with Marty Adler’s eventual retirement from the Executive Officer position. The Long-Range Planning Committee will also play a major role in the process and selection of the new Executive Officer for the College.

You may be aware that conference grants have been limited by the Obama administration to less than $ 100,000, resulting in a funding cut for the 2013 CPDD meeting. CPDD absorbed some of the funding cuts and sponsored travel awards to the 2013 CPDD meeting. The Finance Committee will also be making recommendations about funding travel to the CPDD meeting for new investigators using existing funds in CPDD’s fund balance.

Another effort we are currently engaged in is the scheduling of joint meetings with other scientific societies. We are trying to arrange an overlap meeting with the International Narcotics Research Conference in 2015 and are looking to hold joint meetings with such societies as the Research Society on Alcoholism (2018), the International Cannabis Research Society, and The Society

Continued on page 3
of Neuroimmune Pharmacology. If we are successful the attendees will be able to attend two meetings at a reduced travel cost.

Looking back, looking ahead

The 2013 meeting in San Diego was a relative success, given the travel situation imposed on US Government employees. Most of the comments I heard about the meeting venue and the city of San Diego were very favorable; most of the people I spoke with would like to repeat the experience. Hence, San Diego has been added to the list of potential future meeting sites. A recap of the meeting can be viewed at [http://www.cpdd.vcu.edu/Pages/Meetings/2013Recap.pdf](http://www.cpdd.vcu.edu/Pages/Meetings/2013Recap.pdf). I would like to especially thank Dr. Nora Volkow for interceding with the powers that be at NIH to allow 30 NIDA scientists to attend the 2013 meeting. I know how important it is to have a federal presence at the annual meeting. We like face-to-face meetings with our NIDA project officers to discuss current studies and future proposals. We will be monitoring the federal travel situation and will work with NIDA to have a presence at the 2014 meeting.

I look forward to serving as the organization’s president for the next year. I hope you all have a healthy, productive year and look forward to meeting in June in San Juan.

2013 AWARD WINNERS

The Introductory Remarks and Recipient Comments of the 2013 award winners will be presented across two issues of Newsline.

J. Michael Morrison Award: Redonna Chandler

*Introduction by Michael Dennis*

Through its J. Michael Morrison Award, CPDD seeks to recognize the all too rare combination of first-hand experience, scientific productivity, and leadership the field needs in scientific administration. The 2012 award went to Dr. Redonna Chandler, Chief of NIDA’s Services Research Branch. Dr. Chandler received her training from the University of Kentucky. She has provided service and taught in college settings, medical settings, federal prisons, and judicial training institutes. At NIDA she has expanded the services research branch’s traditional focus on comparative effectiveness, delivery, organization and economic factors to also address implementation science, justice settings, adolescents, and recovery research. She has led multiple cooperative research initiatives including the Criminal Justice Drug Abuse Treatment Study (CJDATS) I & II, Seek Test, Treat, and Retain (STTR) Data Harmonization Initiative, and the Juvenile Justice

Continued on page 4
Award Winners continued from page 3

Translational Research on Interventions with Adolescents in the Legal System (JJ-TRIALS). At the same time she has served on over 20 major federal work groups, including data harmonization and the federal response to Katrina. Academically she has been one of the major authors of NIDA’s principles of addiction treatment, addiction treatment in the justice system, and its upcoming addiction treatment for adolescents, as well as 19 other publications. She has made over 3 dozen presentations at CPDD and other conferences, reviewed for multiple journals, served on editorial boards, and as treasurer and finance chair for APA’s Division of Psychology of Women, and program board for the Joint Meeting on Adolescent Treatment Effectiveness (JMATE). In short, she is the kind of leader we want others to emulate and a great person.

Comments by Redonna Chandler

I want to thank CPDD and those who nominated me for this award. In my career I have been fortunate to be supported by many people including Drs Volkow and Compton at NIDA and my mentors from the University of Kentucky. But I would be remiss if I didn’t acknowledge one group in particular and that is the terrific group of individuals I have the pleasure of working with every day in the Services Research Branch. They are an exceptionally smart, dedicated, talented group of public servants who work tirelessly in the development of research intended to improve the quality of drug abuse and addiction treatment services – and among other things they make me look really good.

We are currently entering a time of unprecedented opportunity to alleviate the suffering caused by drug abuse and addiction. Health care reforms sweeping across this country combined with mental health and substance abuse parity offer the possibility to reach a much wider group of patients and provide them evidence-based treatment.

But realizing this dream will require all of you. As Dr. Volkow likes to say, “we need your brains.” We need you to continue in your research and help us understand the basic mechanisms and neurobiology of addiction, develop new medications and improved behavioral treatments, improve our prevention interventions, and determine the best ways to change the treatment system to implement evidence-based practices. You know, despite budgetary constraints and things like sequestration, I witness NIDA funding extraordinary research every day. And, it could be your research, but only if you submit an application. So, don’t give up and in the words of Winston Churchill, “Never, never, never, quit.” Thank you.

Nathan B. Eddy Award: Linda Dykstra

Introduction by Kathryn Cunningham

I am honored to have introduced Dr. Linda Dykstra, the William Rand Kenan Distinguished Professor at the University of North Carolina (UNC), as the 40th recipient of the Nathan B. Eddy Memorial Award. During her highly meritorious career, Linda has taken the lead in orchestrating cutting-edge research successes in
psychopharmacology, creating novel approaches to her research program, and developing new translational efforts in behavioral neurobiology. Her journey toward this career began following her graduation from Hope College with a B.A. in mathematics and psychology. As a Ford Foundation Fellow in the Humanities, she obtained an M.A. in English Literature and a Ph.D. in psychology at the University of Chicago.

It was during her graduate training in Chicago that Linda enrolled in a Behavioral Analysis course taught by Dr. Israel Goldiamond. This course not only introduced her to the foundations of behavior but was a landmark in cultivating lifelong relationships with course participants James Appel, Marian Fischman, Chris-Ellyn Johanson, Klaus Miczek, and Bob Schuster. This course also drew Linda to her first experiments in animals as a graduate student with Jim Appel. The Dykstra and Appel collaboration resulted in five papers focused on psychoactive drugs, stimulus discrimination and signal detection. Jim Appel recently wrote that “Linda Dykstra was one of the earliest but still one of the very best of the students who worked with me. I am proud to have played a small role in the success that her own intelligence, energy, personality, and persistence made possible.” In sum, I know that these participants in Dr. Goldiamond’s course did not realize what the future held at that moment, but we would all agree that the interactions in the course were highly significant (p < 0.0001), resulting in a cadre of researchers who have had a powerful and indelible impact upon our science.

Linda’s enthusiasm for the emerging area of psychopharmacology also culminated in an enduring collaboration and friendship with Professor Lewis S. Seiden in the Department of Pharmacology at the University of Chicago. The two colleagues conceptualized and completed their pioneering book Psychopharmacology: A Biochemical and Behavioral Approach, over the next few years. Published in 1977, this book was the first truly interdisciplinary textbook in psychopharmacology and was the first to approach this area with a behavioral perspective, establishing a tradition that remains central to this field today. As she continued to write this seminal textbook, Linda was recruited to a postdoctoral position with Don McMillan in the UNC Department of Pharmacology in 1972. This postdoctoral training lasted only nine months because Linda was recruited as Assistant Professor to the UNC Department of Psychology; that nine months, however, was highly productive with four papers published and a resultant lifelong yen to study opiates. Linda’s early years at UNC expanded her circle of influence to include friends and colleagues Don McMillan, Billy Martin, Bill Dewey, Lou Harris and David Leander. As her career progressed, she also extended her conceptual and technical research strengths through two sabbaticals with Bill Morse (Harvard Medical School) and Jim Woods (University of Michigan). Both of these experiences resulted in multiple, well-recognized publications and extended her laboratory’s directions and methodological capacity accordingly.

This year marks not only the 40th year of the Eddy Awards, but also the 40th anniversary of Linda’s sterling academic career at UNC. She has proven to be a scientific giant, internationally known as one of our most astute, productive and energetic leaders, having pioneered the investigation of complex interactions between behavior and neurobiology. Linda’s research has had an immeasurable impact on our understanding of opiate function and pharmacology, immunomodulation, tolerance and dependence, pain and pain perception, and cannabinoid function and pharmacology. Her research successes are particularly notable because they have provided the foundation for testing the preclinical effectiveness of newly designed pharmacological agents, both for the treatment of pain as well as for opioid dependence. She has published over 150 peer-reviewed, primary research publications and reviews, in top-notch journals and edited books.
Since 1977, Linda has sustained continuous support for her research from the National Institute on Drug Abuse (NIDA). Her longest running project has spanned a remarkable 35 years and has been recognized with a 10-year MERIT award, illustrating the importance of her research on a national level. Moreover, in 2006, Linda was especially proud to have been named the Marian W. Fischman Lecturer, a national award honoring contributions of an outstanding woman scientist in research and mentoring in addiction neuroscience.

Linda’s passion and commitment to drug abuse and addiction sciences are matched by her contributions to the elevation of the knowledge base of students at all levels. For those of us who are honored with knowing her, it is easy to see why Linda is exceptionally well regarded as a mentor. As so eloquently stated by Steve Negus in his Eddy nomination letter for Linda, “she inspired me to study behavioral pharmacology, equipping me with the intellectual and technical skills to pursue that interest, and modeled the best practices of mentoring. I am perhaps even more moved by the respect she receives outside the limelight, in private conversations when friends or colleagues comment on her integrity, her generosity, or the strength of her research.”

These comments underscore her success in so many roles, including Dean of the UNC Graduate School and Director of a NIDA-funded predoctoral training grant in drug abuse; Linda directed the training grant for over 20 years and oversaw the graduation of close to 55 Ph.D. students. In recognition of her strong emphasis on training future researchers in the field of drug dependence, Linda received the 2005 CPDD Mentorship Award for which she was nominated by a subset of her 20+ predoctoral and 10+ postdoctoral students, and it is most noteworthy that so many of these trainees have gone on to successful academic/research careers, carrying with them the interdisciplinary approaches that are so central to Linda’s research excellence. Linda has also held numerous research-related appointments, including membership on the NIDA National Advisory Council, the Board of Directors for two research institutes and three societies, the Board of Trustees for two centers, as well as the Field Editor for Journal of Pharmacology and Experimental Therapeutics, a highly respected journal in pharmacology. Linda has served effectively as a member of the CPDD Board of Directors twice (1992-1998; 2011-2013) and was CPDD -President (1997-1998). These accomplishments are a testament to Linda’s leadership acumen.

What is not apparent in my comments so far is that Linda has sustained this exemplary career simultaneously with two other exemplary careers. First, she is the devoted spouse of Bill Hylander with this collaboration is in its 41st year. Linda is also a mother to her son Grayson and daughter Becca and son-in-law Mike. Most excitingly, Linda and Bill will become grandparents soon as Becca and Mike are expecting a baby boy this fall. The Dykstra-Hylander family own and operate a working farm in southwest Virginia, which probably counts, in itself, as yet another career.

In summary, Dr. Eddy would be proud of this year’s awardee. Linda has a remarkable record of research productivity, mentorship and leadership success and has served as a visionary in the drug abuse field. Her science is enduring, her mentees have followed in her footsteps and have themselves accomplished countless scientific advances and the training of new members of our research and educational community in psychopharmacology. In addition, Linda is a highly valued and respected member of our community at large and has placed a tremendous amount of effort into building a cross-disciplinary research program that draws from multiple aspects of preclinical and clinical science. Isaac Newton said it first, and I will paraphrase: I think we all see farther by standing on the shoulders of our giant, Dr. Linda Dykstra.
Lecture by Linda Dykstra
“In Search of a Better Analgesic”

I am particularly honored to receive the Nathan B. Eddy award at such an important juncture in CPDD history. In 2013, as we celebrated 75 years of CPDD meetings, I have focused my presentation on another 75+ year undertaking that parallels the history of CPDD, i.e., the search for a better analgesic. That search, which was initiated by Nathan B. Eddy and sustained by numerous CPDD scientists has been the focus of my own research over the last 40 years.

Now 75 or more years is a long time to be searching for a better analgesic and one might wonder why it is taking so long. One reason, of course, is that the challenges associated with treating pain are enormous. Moreover, the class of drugs—the opioids—that are most effective in treating intense pain have many limitations. They can compromise respiration, blur sensation, produce constipation, become less effective when used repeatedly and, in some individuals, lead to dependence. Importantly, problems related to opioid dependence have escalated in the last 10-20 years, and much of that increase is related to the development of long-acting, sustained-release opioids, resulting in the current epidemic of prescription drug abuse.

In short, there is still a pressing need to identify better analgesics, or if not a better analgesic, better ways to treat pain. To put the search for a better analgesic in perspective, let’s go back to the 1930s-60s. During that time the search for a better analgesic was marked by exploration of opioid structure-activity relationships, yielding hundreds of new compounds based on modifications of the opioid structure. Several of those compounds found their way into the clinic, including some that are commonly used today such as codeine, methadone, hydrocodone, oxycodone, buprenorphine and fentanyl. Although none of the compounds developed during that period were without some degree of addiction liability, they did offer certain advantages. Some were longer- or shorter-acting; others were orally active or produced somewhat less dependence. Moreover, the overall search for a better analgesic led to other important findings. For example, knowledge of the mechanisms of tolerance and dependence saw marked advances. New methods for measuring analgesia and dependence were introduced and research strategies became more interdisciplinary, drawing on the expertise of chemists, pharmacologists and behavioral scientists. Within the clinic, questions about balancing abuse potential with the benefits of effective pain relief were becoming more common.

My own slice of this long running search began in 1973, about the time multiple opioid receptors had been identified. This was also the same year that I attended my first CPDD meeting and accepted a faculty position in the Psychology Department at the University of North Carolina at Chapel Hill. So let’s start here, with the possibility that a better analgesic might be

Continued on page 8
found through selective action at distinct opioid receptor types. Our laboratory, along with many others, hypothesized that drugs which targeted the kappa or the delta opioid receptor type might hold promise as better analgesics, without the unwanted effects of mu agonists. The search within our laboratory began with the development of the squirrel monkey titration procedure, which allowed us to separate a drug’s ability to alter sensitivity for a potentially painful stimulus from other factors that might alter an organism’s tendency to respond, such as sedation. Our research program was enriched by collaborations with chemists and pharmacologists from industry and academia and expanded by the curiosity of an outstanding group of colleagues and students, most of whom are actively involved in CPDD today.

First, we verified the analgesic profile of morphine (and other mu opioids, including the partial mu agonist, buprenorphine) in our animal procedures. Mu agonists produced dose-dependent increases in the level at which squirrel monkeys would maintain a potentially uncomfortable stimulus by responding on a lever. Importantly, those increases occurred at doses that did not decrease overall rates of responding. With this profile in mind, we examined a large number of kappa and delta agonists. Data from our laboratory showed that the kappa agonists produced minimal tolerance, no cross-tolerance with mu opioids, and a mild level of physical dependence. Unfortunately, these promising indications weren’t matched by efficacy on the analgesia side. Moreover, the kappa agonists produced their own type of sedation and prominent dysphoria as revealed by studies in human subjects. Examination of drugs selective for the delta opioid receptor type provided yet another profile with minimal tolerance, subtle dependence, very little respiratory depression, but unfortunately limited analgesic efficacy.

From one perspective, one might conclude that the mu/kappa/delta strategy amounted to a failed search. It had not identified an analgesic that was just as effective as morphine, but without dependence liability or other unwanted effects. From another perspective, there was much to be gained from this ongoing, collaborative search. Knowledge about pain systems increased and understanding of opioid pharmacology advanced. Importantly, the role of behavioral factors in the pain experience was acknowledged. Moreover, at least one compound identified in the search, the partial mu agonist, buprenorphine, found a prominent place in the treatment of opioid abuse, since its more moderate profile as an analgesic went hand in hand with a lesser degree of dependence and reduction in withdrawal symptoms.

Following on research related to opioids selective for mu, kappa or delta opioid receptor types, our laboratory took a new approach, namely the exploration of drug combinations. With this approach, we hypothesized that if morphine were combined with a drug that potentiated its analgesic effects, then a lower dose of morphine could be given, and that lower dose might be expected to produce less tolerance, less respiratory depression, less dependence…less of everything that wasn’t desirable, while pain relief remained the same.

In many ways, the results of those investigations were promising. Research led by Rich Allen and Brad Fischer in our laboratory indicated that NMDA antagonists, when combined with a mu agonist such as morphine, could attenuate tolerance and shift the morphine curve to the left, suggesting that analgesia might be achieved with a lower dose of morphine, producing in turn, a lesser degree of tolerance and dependence. In parallel, Laurence Miller showed that cannabinoid/opioid combinations also held promise, not only for potentiating the analgesic effects of an opioid, but also for restoring behaviors (feeding, motor activity) that were decreased by the pain experience. With Rebecca Balter, we carried out a series of studies suggesting that the opportunity to engage in
alternative behaviors, such as running in an exercise wheel, could attenuate the increases in pain sensitivity that often accompany withdrawal from long-term opioid administration.

In closing, it is clear that the search for a better analgesic is not over. Clearly, new analgesics need to be developed with careful consideration for the presence of unwanted effects such as dependence and abuse. At the same time, we can’t simply wait on the development of a new, improved analgesic. The search for more effective ways to treat opioid dependence needs to take place in parallel — building on the expertise of CPDD and its dedicated members.

Acknowledging inspiration and support from:
Mentors and colleagues: Jim Appel, Lew Seiden, Bob Schuster, Don McMillan, Bill Dewey, Lou Harris, Steve Holtzman, Bill Morse, Jim Woods, Ivy Carroll, J. David Leander, Laura Bohn and Mitch Picker
Graduate students and postdoctoral fellows: Margaret Healey, Jeff Witkin, Richard Carter, Ray Genovese, Allison Oliveto, Steve Negus, Pam Doty, Rebecca Craft, Adande Mattox, Andrew Johnson, Ray Pitts, Chris Hughes, Kelly Powell, Ellen Walker, Kelly Carrigan, Sara Ward, Rich Allen, Brad Fischer, Laurence Miller, Rebecca Balter
Friends: Chris Johanson, Marian Fischman, Bob Balster, Klaus Miczek, Kathy Cunningham, Mike Nader
Family: Bill, Gray, Becca and Mike

CALL FOR NOMINATIONS
PRESIDENT-ELECT AND BOARD MEMBERS

Nominations for President-Elect of the College, and for members of the Board of Directors are being sought. The continued success of the election process depends on your participation. More importantly, the rapidly changing terrain in NIH funding, organizational structure of NIDA and NIAAA, and the political tone in Washington is heralding what will be extremely important times for the College. Specifically, we will need committed individuals who are willing to take a leadership role to help us navigate the obstacles and opportunities that await us in the coming years.

Nominations will be evaluated by the Nominating Committee, which will then formulate a slate of candidates. The members of the 2013-2014 Nominating Committee include Eric Strain (chair), Anna Rose Childress, Andrew Coop, Linda Dwoskin, Meg Haney, Carl Hart, Gregory Miller, Linda Porrino and Rumi Price. Members of the Committee are not eligible for election.

President-Elect: A nominee must be a current member of the Board of Directors, or have been a member of the Board or an officer within the last three years. A list of eligible candidates is included below. The candidate who is elected will assume the office of President-Elect, and then President, and Past-President immediately following the Annual Scientific Meetings in June of 2014, 2015, and 2016, respectively.


Board of Directors (BOD): There are four BOD positions to fill. This is an outstanding way to serve the College and further its interests. Please consider nominating candidates who have served the College on

Continued on page 11
Notable Committee News

Program Committee
Applications for submission of symposium and workshops for the 2014 meeting are now available on the CPDD website and the due date is October 15th, 2013. Questions regarding symposia can be directed to Elise Weerts (eweerts@jhmi.edu). Please include “CPDD” in the subject header line.

Membership Committee
The Membership Committee wanted to share a graph showing the increase in membership since 2004.

Education, Outreach and Public Policy Committee
The membership survey indicated strong interest in a presentation on health care reform. Dennis McCarty and Martin Iguchi will be arranging a panel on the reform for the 2014 meeting and will build on recent NIDA awards to assess the impacts of health care reforms on treatment for alcohol and drug use disorders. The Committee’s work plan for next year includes a) a policy presentation on the Affordable Care Act and its implications at next year’s meeting, b) continued work with the Media Committee on media training; c) continued work with Bill Dewey and the Friends of NIDA, and d) continued encouragement for members to become active in advocacy efforts.

International Committee
We are pleased to advise that the CPDD/NIDA/WHO Travel Award Scheme for 2014 will include 3 years of registration for the CPDD meeting rather than one year as before. This will enhance the engagement of the successful scholar with the CPDD community and build sustainable collaborations with US scholars and research groups supported by NIDA. Please check the CPDD website for further information.

Committee on the Abuse Liability of Drugs
The Abuse Deterrence Formulation Science Meeting on the FDA Draft Guidance (Sept. 30 – Oct. 1, 2013, North Bethesda Marriott Hotel and Conference Center) is being facilitated with the aid of the committee and CPDD. In January 2013 the FDA has released the Draft Guidance for Industry: Abuse Deterrent Opioids – Evaluation and Labeling. The goal of this meeting is to provide an open forum enabling discussion and recommendations on the Draft Guidance and to provide an opportunity for presentations by experts addressing this document. It is organized by the Cross-Company Abuse Liability Consortium, CCALC, facilitated with the aid of CPDD, and will include presentations by the FDA representatives including Dr. Throckmorton. More information about this meeting and registration can be found at www.adfsciencemeeting.com

Publication Committee
The Publication Committee is working on a new project this year to highlight advice for new drug abuse researchers from leaders in the field. We’re recruiting mentees of past Eddy Award winners to interview their mentors on their advice for achieving excellence in the field. Stay tuned to learn more, and if you’re interested in helping out please email Rajeev Ramchand at ramchand@rand.org
Call for Nominations continued from page 9

committees and regularly attend the Annual Scientific Meeting. Those elected will begin a 4-year term immediately following the Annual Scientific Meeting in June, 2014. Except under unusual circumstances, nominees are members of the College. By long tradition, candidates for membership on the Board of Directors have been selected with the goal of ensuring that the Board will continue to reflect the broad diversity of its constituency. Representation of a broad range of scientific interests is crucial.

One of the ways this diversity has been maintained has been to select nominees with areas of interest that are similar to those of departing Board members. The departing members include Andrew Coop (Drug Development, Medicinal Chemistry), Linda Cottler (Epidemiology), Mary Jeanne Kreek (Research Physician, Treatment Research), and Roger Spealman (Behavioral Pharmacology). Former members of the Board of Directors who wish to be nominated must wait a minimum of three years since they last served on the Board.

Nominations must include a short biographical sketch (please obtain from the nominee or request that he/she submit it), full mailing address, telephone number, fax number and e-mail address. Also, indicate the nomination position of President-Elect or Board of Directors. You may send nomination by e-mail to nsmith02@temple.edu. Please, no faxes or mailings.

Please be sure to confirm that your nominee is willing to be a candidate and to serve, if elected. Furthermore, if you are interested in serving, you are strongly encouraged to nominate yourself! Nominations must be received in Dr. Martin Adler’s office no later than November 7, 2013. Incomplete nominating information will not be accepted.

SEARCH FOR A NEW CPDD EXECUTIVE OFFICER

The Executive Committee and Board of Directors of the College on Problems of Drug Dependence (CPDD: www.cpdd.org) are pleased to announce the search for a new Executive Officer (E.O.) who will succeed Dr. Martin Adler. CPDD has been in existence since 1929 and is the longest standing group in the USA addressing problems of drug dependence and abuse. Currently, CPDD has over 1,000 members and the organization serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field.

The responsibilities of the E.O. are to represent CPDD in dealings with government, industry, academia, and other organizations as
related to policy positions, joint initiatives, funding and other issues that may arise. The E.O. is
ad hoc to all committees of CPDD. He/she is responsible for overseeing the work of the various
committees of CPDD, giving advice and direction when needed, and preparing, in collaboration
with the Director of the Executive Office (Ellen Geller) the annual meeting grant from NIDA, on
which he/she is both the P.I. and the Signing Officer for the organization. The E.O. is the official
signatory for CPDD in all legal matters, including federal, state, and local forms, as well as items
related to insurance. The E.O. serves as a non-voting member of the Executive Committee and is
a member of the Finance Committee. The E.O. works with Friends of NIDA and Von Scoyoc in
educating members of Congress on issues related to drug abuse funding and policy. The E.O.
also assists in setting up meetings with which CPDD is associated, including the annual
scientific meeting of CPDD held at various locations in June of each year.

In order to accomplish the larger goals of the organization, the E.O. has to be able to work with
all of the constituencies of the organization, including the Director of the Executive Office, the
membership, the Officers, the Board of Directors (BOD), and the Committee Chairs. Many issues
arise that require negotiating skills, people skills, and good judgment. It is the responsibility of
the E.O. to integrate all of CPDD activities that have been authorized by the BOD and the
officers of CPDD. In summary, the E.O. has a leadership role in CPDD and is responsible to the
Executive Committee and BOD of CPDD.

Characteristics strongly recommended for candidates:
Doctoral degree (Ph.D., M.D., Psy.D., etc) and a faculty appointment at a university, medical
school or other institution at the level of Professor or equivalent;
History of NIH funding as a PI in the fields covered by CPDD’s membership, especially
addiction and drug abuse;
Documented history of administrative and/or leadership experience;
Substantial history of service to CPDD through membership on committees, elected member of
BOD, or previous elected officer of CPDD;
History of robust attendance (i.e., at least 7 of last 10 years) and presenting at CPDD; and
Ability to commit up to 50% of effort for the position.

Interested candidates should submit a one-page letter of interest, recent CV, and answers to the
questions below to Richard De La Garza, II, Ph.D. (Chair of the E.O. Search Committee) by
October 15, 2013. All documents should be submitted electronically as one file to rg12@bcm.edu.
Questions about the position should be E-mailed directly to Dr. De La Garza.

Please address the following (maximum 3-pages):
Describe your scientific background and experience.
Describe current responsibilities and how you will reallocate effort to accommodate this
position.
Describe your administrative/leadership experience.
How available would you be to travel to Washington DC or other locations for CPDD business?
Discuss your vision for CPDD and how CPDD can best serve the substance abuse research
community in the future.
How do you envision interacting with the CPDD office* at Temple University?

*Information provided upon request